These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 31592212)
1. Synthesis of a C O'Neil GW; Craig AM; Williams JR; Young JC; Spiegel PC Synlett; 2017 Jun; 28(9):1101-1105. PubMed ID: 31592212 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of the C Swick SM; Schaefer SL; O'Neil GW Tetrahedron Lett; 2015 Jun; 56(26):4039-4042. PubMed ID: 26257444 [TBL] [Abstract][Full Text] [Related]
3. Suzuki coupling-based synthesis of VATPase inhibitor archazolid natural product derived fragments. Vincent CT; Long ET; Jones HC; Young JC; Spiegel PC; O'Neil GW RSC Adv; 2019 Oct; 9(55):32210-32218. PubMed ID: 35530773 [TBL] [Abstract][Full Text] [Related]
4. Total Synthesis of Biselyngbyolide B and Its C21-C22 Z-Isomer. Kämmler L; Maier ME J Org Chem; 2018 Apr; 83(8):4554-4567. PubMed ID: 29589751 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs. Scheeff S; Rivière S; Ruiz J; Abdelrahman A; Schulz-Fincke AC; Köse M; Tiburcy F; Wieczorek H; Gütschow M; Müller CE; Menche D J Med Chem; 2020 Feb; 63(4):1684-1698. PubMed ID: 31990540 [TBL] [Abstract][Full Text] [Related]
6. Archazolid A-15-O-β-D-glucopyranoside and iso-archazolid B: potent V-ATPase inhibitory polyketides from the myxobacteria Cystobacter violaceus and Archangium gephyra. Horstmann N; Essig S; Bockelmann S; Wieczorek H; Huss M; Sasse F; Menche D J Nat Prod; 2011 May; 74(5):1100-5. PubMed ID: 21513292 [TBL] [Abstract][Full Text] [Related]
7. Modular total synthesis of archazolid A and B. Menche D; Hassfeld J; Li J; Mayer K; Rudolph S J Org Chem; 2009 Oct; 74(19):7220-9. PubMed ID: 19739663 [TBL] [Abstract][Full Text] [Related]
8. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050 [TBL] [Abstract][Full Text] [Related]
10. The first hydroxylated archazolid from the myxobacterium Cystobacter violaceus: isolation, structural elucidation and V-ATPase inhibition. Menche D; Hassfeld J; Steinmetz H; Huss M; Wieczorek H; Sasse F J Antibiot (Tokyo); 2007 May; 60(5):328-31. PubMed ID: 17551213 [TBL] [Abstract][Full Text] [Related]
11. Targeting V-ATPase in primary human monocytes by archazolid potently represses the classical secretion of cytokines due to accumulation at the endoplasmic reticulum. Scherer O; Steinmetz H; Kaether C; Weinigel C; Barz D; Kleinert H; Menche D; Müller R; Pergola C; Werz O Biochem Pharmacol; 2014 Oct; 91(4):490-500. PubMed ID: 25107704 [TBL] [Abstract][Full Text] [Related]
12. Total syntheses of the archazolids: an emerging class of novel anticancer drugs. Scheeff S; Menche D Beilstein J Org Chem; 2017; 13():1085-1098. PubMed ID: 28684988 [TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B. Hamm R; Sugimoto Y; Steinmetz H; Efferth T Invest New Drugs; 2014 Oct; 32(5):893-903. PubMed ID: 25065443 [TBL] [Abstract][Full Text] [Related]
14. Modular Total Synthesis of Scheeff S; Rivière S; Ruiz J; Dedenbach S; Menche D J Org Chem; 2021 Aug; 86(15):10190-10223. PubMed ID: 34293866 [TBL] [Abstract][Full Text] [Related]
15. Selective upregulation of TNFα expression in classically-activated human monocyte-derived macrophages (M1) through pharmacological interference with V-ATPase. Thomas L; Rao Z; Gerstmeier J; Raasch M; Weinigel C; Rummler S; Menche D; Müller R; Pergola C; Mosig A; Werz O Biochem Pharmacol; 2017 Apr; 130():71-82. PubMed ID: 28189727 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT. Merk H; Messer P; Ardelt MA; Lamb DC; Zahler S; Müller R; Vollmar AM; Pachmayr J Mol Cancer Ther; 2017 Nov; 16(11):2329-2339. PubMed ID: 28775146 [TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Zhang S; Schneider LS; Vick B; Grunert M; Jeremias I; Menche D; Müller R; Vollmar AM; Liebl J Oncotarget; 2015 Dec; 6(41):43508-28. PubMed ID: 26496038 [TBL] [Abstract][Full Text] [Related]
18. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Wiedmann RM; von Schwarzenberg K; Palamidessi A; Schreiner L; Kubisch R; Liebl J; Schempp C; Trauner D; Vereb G; Zahler S; Wagner E; Müller R; Scita G; Vollmar AM Cancer Res; 2012 Nov; 72(22):5976-87. PubMed ID: 22986742 [TBL] [Abstract][Full Text] [Related]
19. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. von Schwarzenberg K; Wiedmann RM; Oak P; Schulz S; Zischka H; Wanner G; Efferth T; Trauner D; Vollmar AM J Biol Chem; 2013 Jan; 288(2):1385-96. PubMed ID: 23168408 [TBL] [Abstract][Full Text] [Related]
20. Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. Sasse F; Steinmetz H; Höfle G; Reichenbach H J Antibiot (Tokyo); 2003 Jun; 56(6):520-5. PubMed ID: 12931860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]